Megan Pace Joins Moderna as Chief Corporate Affairs Officer

CAMBRIDGE, Mass., April 4, 2018 — Moderna Therapeutics, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Megan Pace has joined Moderna as Chief Corporate Affairs Officer. She will serve on Moderna’s Executive Committee and report to Chief Executive Officer Stéphane Bancel.

“I am thrilled to welcome Megan to Moderna. As a rapidly growing organization, we will benefit from her extensive public affairs experience and prior leadership roles at biotech companies that have made the successful transition from research and development to their first product launches,” said Stéphane Bancel, Chief Executive Officer. “Megan has a deep understanding of the complexity of drug development and commercialization globally, and I look forward to having her on the Moderna Executive Committee.”  

“I am excited to join Moderna at an important time in the Company’s efforts to bring potentially transformative mRNA medicines through the pipeline and to patients,” said Pace. “I look forward to developing relationships with key stakeholders and increasing awareness of the work being done by Moderna scientists and clinicians in pursuit of this new class of vaccines and therapies.”

Ms. Pace has nearly 20 years of communications, government affairs, patient advocacy, investor relations, program leadership and corporate planning experience in the biotech sector, including prior executive team roles at Agios Pharmaceuticals and Vertex Pharmaceuticals. Prior to Moderna, she served as Senior Vice President, Strategic Operations and PKR Program Executive at Agios; Senior Vice President, Corporate Communications at Vertex; and Senior Director, Public Affairs at Genentech. She also worked on the communications and government affairs teams at Eli Lilly and Company, as well as at Porter Novelli, a global public relations firm.

Ms. Pace holds a B.A. from the College of Charleston. She is a board member of the Boomer Esiason Foundation and the Make-a-Wish Foundation of Massachusetts and Rhode Island.

About Moderna Therapeutics

Moderna pioneers the discovery and development of messenger RNA (mRNA) therapeutics and vaccines, an entirely new class of medicines that directs the body’s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals. With its breakthrough platform, Moderna is creating mRNA medicines for a wide range of diseases and conditions, in many cases by addressing currently undruggable targets or underserved areas of medical need. Moderna is developing its innovative mRNA medicines for infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases, through solely controlled programs and collaborations with strategic partners.

Headquartered in Cambridge, Mass., privately held Moderna currently has strategic relationships with AstraZeneca, Plc. (AZ), Merck, Inc (MRK) and Vertex Pharmaceuticals (VRTX), as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS); and the Bill & Melinda Gates Foundation. In 2017, Moderna was ranked a top biopharma industry employer by Science Magazine and a Top Places to Work by the Boston Globe. To learn more, visit www.modernatx.com.

Moderna Contacts

Investors:
Lorence Kim
617-209-5849
lorence.kim@modernatx.com

Media:
media@modernatx.com